UNSPSC 51312507: Dimetindene maleate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H24N2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6LL60J9E0O, chemically known as 1h-indene-2-ethanamine, n,n-dimethyl-3-(1-(2-pyridinyl)ethyl)-, (z)-2-butenedioate (1:1) but more generally known as dimethindene maleate, which bears US NIH Compound Identifier 5282414. European Medicines Agency schedules Dimetindene maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01754MIG.

Most nations, for tariff and trade purposes, schedule dimetindene maleate under HS 29333999. SMILES: CC(C1CCCCN1)C2=C(CC3C2CCCC3)CCN(C)C.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51312507 Dimetindene maleate is a Commodity code representing pharmaceutical products procured by state and local health and human services agencies, though the recent opportunities show minimal direct demand tagged specifically to this code. State and local governments acquiring under this code are primarily health departments, state pharmacy benefit programs, and county community health systems seeking to stock pharmaceutical inventories for public health initiatives and subsidized or emergency dispensing programs. The scope of work involves supply of finished pharmaceuticals meeting FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements, with vendors responsible for maintaining appropriate inventory levels, managing expiration-date compliance, and ensuring products remain available through authorized distribution channels.

Recent activity shows limited direct procurement under this specific code. The three most visible opportunities involve related but broader pharmaceutical purchasing: Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023), the Texas Health and Human Services Commission's RFI into direct-to-manufacturer prescription programs (posted April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026). The MMCAP procurement, administered through the Minnesota Department of Administration and open to participating state and local entities including Oregon, represents the largest current cooperative purchasing vehicle for pharmaceutical supply across multiple jurisdictions. None of these opportunities explicitly reference dimetindene maleate by name, suggesting the code sees minimal standalone solicitation activity at the state and local level; procurement in this category typically occurs through broader generic-pharmaceutical and OTC-product aggregated awards rather than single-ingredient targeted buys.